To prepare future clinical studies for its first-in-class monoclonal antibody targeting neurovascular and neurodegenerative disorders.
A novel biotherapy targeting the blood-brain barrier dysfunctions to treat patients suffering from disabling neurological diseases
Lys Therapeutics, a French biotech company developing innovative treatments for neurological and neurodegenerative diseases, announced today its first fundraising of 5.5 million euros. This seed round of financing consists of 3 million euros in equity investment led by a consortium of qualified investors including HTH VC, and 2.5 million euros in grants, loans and repayable advances through Bpifrance, as well as other banking institutions.